(Q38014646)

27 August 2017

Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care (English)

1 reference

27 August 2017

1 reference

1 reference

1 reference

Brian L Pearlman

1

1 reference

27 August 2017

29 May 2012

1 reference

Lancet Infectious Diseases

27 August 2017

1 reference

27 August 2017

12

1 reference

27 August 2017

9

1 reference

27 August 2017

717-728

1 reference

Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium

27 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970060-9

7 January 2021

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970060-9

7 January 2021

Unravelling hepatitis C virus replication from genome to function

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970060-9

7 January 2021

Regulation of Interferon Regulatory Factor-3 by the Hepatitis C Virus Serine Protease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970060-9

7 January 2021

Product inhibition of the hepatitis C virus NS3 protease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970060-9

7 January 2021

Boceprevir for untreated chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970060-9

7 January 2021

Boceprevir for previously treated chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970060-9

7 January 2021

Telaprevir for previously untreated chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970060-9

7 January 2021

Telaprevir for retreatment of HCV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970060-9

7 January 2021

Response-guided telaprevir combination treatment for hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970060-9

7 January 2021

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970060-9

7 January 2021

Evaluation of early null response to pegylated interferon and ribavirin as a predictor of therapeutic nonresponse in patients undergoing treatment for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970060-9

7 January 2021

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970060-9

7 January 2021

Telaprevir for previously treated chronic HCV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970060-9

7 January 2021

Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970060-9

7 January 2021

Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970060-9

7 January 2021

EASL Clinical Practice Guidelines: management of hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970060-9

7 January 2021

Boceprevir for chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970060-9

7 January 2021

Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970060-9

7 January 2021

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970060-9

7 January 2021

Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970060-9

7 January 2021

Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (VX-950) and danoprevir (ITMN-191).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970060-9

7 January 2021

Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970060-9

7 January 2021

Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970060-9

7 January 2021

Phenotypic Characterization of Resistant Val36 Variants of Hepatitis C Virus NS3-4A Serine Protease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970060-9

7 January 2021

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970060-9

7 January 2021

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970060-9

7 January 2021

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970060-9

7 January 2021

Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970060-9

7 January 2021

The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970060-9

7 January 2021

Replication of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970060-9

7 January 2021

Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970060-9

7 January 2021

Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970060-9

7 January 2021

Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970060-9

7 January 2021

Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970060-9

7 January 2021

Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970060-9

7 January 2021

Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970060-9

7 January 2021

Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970060-9

7 January 2021

Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970060-9

7 January 2021

Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970060-9

7 January 2021

Public health impact of antiviral therapy for hepatitis C in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970060-9

7 January 2021

Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970060-9

7 January 2021

A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970060-9

7 January 2021

Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970060-9

7 January 2021

New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970060-9

7 January 2021

Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970060-9

7 January 2021

Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination therapy in human hepatocyte chimeric mice

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970060-9

7 January 2021

Preliminary study of two antiviral agents for hepatitis C genotype 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970060-9

7 January 2021

Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2812%2970060-9

7 January 2021

10.1016/S1473-3099(12)70060-9

Identifiers

DOI

1 reference

27 August 2017

1 reference

PubMed ID

22647717